Imbed Biosciences Announces CMS Assignment of HCPCS Code for Microlyte® PainGuard™

New code supports billing clarity and claims reporting for synthetic antimicrobial wound matrix with localized pain management.

Apr. 2, 2026 at 7:21am

Got story updates? Submit your updates here. ›

Imbed Biosciences, a medical device company, announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a Healthcare Common Procedure Coding System (HCPCS) Level II code, A2040, to Microlyte® PainGuard™, the company's synthetic wound matrix that incorporates silver for antimicrobial activity and lidocaine HCl for localized pain management. The new code, effective April 1, 2026, enables healthcare providers to report the product on claims submitted to payers that recognize HCPCS Level II codes.

Why it matters

The assignment of an HCPCS code is an important step in supporting appropriate billing and claims visibility for Microlyte® PainGuard™, which is designed to provide a fully synthetic, antimicrobial, moist wound-healing environment while incorporating non-opioid, localized pain management functionality. This designation helps provide clarity for providers as they incorporate the product into their clinical workflows.

The details

Microlyte® PainGuard™ is Imbed's recently introduced product that builds on the company's Synthetic Antimicrobial Matrix (SAM) Technology platform. The product is intended to support wound care across a range of acute and chronic indications. HCPCS Level II codes are used to identify products, supplies, and services not described by CPT® codes and are maintained by CMS through its national HCPCS coding process. Assignment of a Level II code allows for standardized product identification on healthcare claims and may support administrative efficiency for providers and payers.

  • The new HCPCS code A2040 for Microlyte® PainGuard™ is effective April 1, 2026.

The players

Imbed Biosciences

A privately held medical device company advancing the next generation of wound care through its Synthetic Antimicrobial Matrix Technology.

Centers for Medicare & Medicaid Services (CMS)

The federal agency that manages the Medicare program and partners with state governments to administer Medicaid.

Terry Bromley

The CEO of Imbed Biosciences.

Got photos? Submit your photos here. ›

What they’re saying

“Assignment of an HCPCS A‑code is an important step in supporting appropriate billing for Microlyte® PainGuard™. This designation helps provide clarity for providers as they incorporate the product into their clinical workflows.”

— Terry Bromley, CEO of Imbed Biosciences

What’s next

The new HCPCS code A2040 for Microlyte® PainGuard™ is effective April 1, 2026, enabling healthcare providers to report the product on claims submitted to payers that recognize HCPCS Level II codes.

The takeaway

The assignment of an HCPCS code for Imbed's Microlyte® PainGuard™ wound matrix represents an important step in establishing billing clarity, supporting claims visibility, and facilitating payer engagement as providers evaluate the appropriate use of this product that combines antimicrobial and localized pain management functionality.